Workday has a track record of beating analyst estimates, but that doesn’t mean its shares will respond accordingly.
Noble Group bids farewell to its CEO and one of its best-performing businesses, hardly signs things are getting back to normal.
Amid high hopes, investors shouldn’t forget how tricky cancer-drug development is.
By lowering its return targets, Wells Fargo has signaled a continued soft environment for banks.
Dalian Wanda Commercial’s plan to delist so soon after its IPO reeks of expedience, rather than long-term value creation. Investors may have little choice but to move on.
The U.S. economy isn’t as weak as the GDP report suggests. As that becomes clear, companies will need to find another excuse.
Energy Transfer Equity’s counterclaims in a suit against Williams Cos are hard to swallow.
After Zoomlion abruptly pulled the plug on buying U.S. equipment maker Terex, other potential takeover targets might want to grill their Chinese suitors on whether they have the cash, or are truly willing to pay the price.
Risk appetite has recovered since the panic at the start of the year. Or has it?